Jobs
-
Tiziana Life Sciences has published results from a pilot study of its intranasal Foralumab in mild to moderate COVID-19 demonstrating that nasal administration of the human anti-CD3 monoclonal antibody was well tolerated and significantly reduced… Read more . . .
-
Aptar Pharma will have 12 months to decide whether to exercise an exclusive option to acquire worldwide rights to Pharmaxis’s high payload Orbital dry powder inhaler under a new agreement, the company said. The Orbital… Read more . . .
-
According to a LinkedIn post by generic device maker Merxin, the FDA has indicated that Merxin’s MRX004 soft mist inhaler is suitable for an ANDA submission for a generic version of Boehringer Ingelheim’s Spiriva Respimat… Read more . . .
-
Philip Morris International (PMI) has acquired inhaled drug developer OtiTopic, as “part of PMI’s strategic plan to leverage its expertise, scientific know-how, and capabilities in inhalation to grow a pipeline of inhaled therapeutics and respiratory… Read more . . .
-
Ji Xing Pharmaceuticals has acquired Chinese development and commercialization rights to Oyster Point Pharma’s OC-01 varenicline nasal spray and OC-02 simpinicline nasal spray for the treatment of dry eye disease in a deal that includes… Read more . . .
-
According to ReCode Therapeutics, studies of its nebulized lipid nanoparticle DNAI1 mRNA therapy for the treatment of primary ciliary dyskinesia in non-human primates demonstrated that a single dose of the mRNA could be delivered successfully… Read more . . .
-
According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry… Read more . . .
-
Berry Global has announced that it will construct a new facility in Bangalore, India that will serve as an R&D center and will add manufacturing capacity for devices, including nasal spray pumps and inhalers, to… Read more . . .
-
MannKind and NRx Pharmaceuticals will work together on a possible inhaled dry powder aviptadil based on MannKind’s Technosphere particle technology, the companies have announced. MannKind said that it would conduct the feasibility study at its… Read more . . .
-
According to Relief Therapeutics, the FDA has granted orphan drug designation for RLF-100 inhaled aviptadil for the treatment of sarcoidosis; RLF-100 is currently in Phase 2 development for that indication. Relief also recently acquired German… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden